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Gヴ;┗Wゲげ disease can be treated with antithyroid drugs (ATDs), radioiodine or surgery. Use of 
definitive treatments (radioiodine or surgery) varies widely across centres. Specific clinical 
circumstances, local facilities, patient and clinician preferences and perceptions will affect choice 
of treatment. Detailed understanding of UK cliniciansげ ┗ｷW┘ゲ ;ﾐS デｴWｷヴ ヴ;デｷﾗﾐ;ﾉW aﾗヴ different 
treatments is lacking. 
Aims: To study the preferences and perceptions of UK clinicians on the role of surgery and 
radioiodine ｷﾐ デｴW ﾏ;ﾐ;ｪWﾏWﾐデ ﾗa Gヴ;┗Wゲげ SｷゲW;ゲWく 
Methods: British Tｴ┞ヴﾗｷS AゲゲﾗIｷ;デｷﾗﾐげ ふBTAぶが け“ﾗIｷWデ┞ aﾗヴ EﾐSﾗIヴｷﾐﾗﾉﾗｪ┞げ ふ“FEぶ ;ﾐS けBヴｷデｷゲｴ 
AゲゲﾗIｷ;デｷﾗﾐ ﾗa EﾐSﾗIヴｷﾐW ;ﾐS Tｴ┞ヴﾗｷS “┌ヴｪWﾗﾐゲげ ふBAET“ぶ members were invited to complete an 
online survey examining their management decisions in Gヴ;┗Wゲげ disease and factors that 
influenced their decisions. 
Results: 158 responses from UK consultants were included. The ratio of physicians to surgeons 
was 11:5 and males to females was 12:4. Most clinicians would commence ATDs in uncomplicated 
first presentation of Gヴ;┗Wゲげ disease. A wide range of risk estimates on the effectiveness and risks 
of treatment was given by clinicians. Radioiodine was ┌ゲWS ﾏﾗゲデ aヴWケ┌Wﾐデﾉ┞ ｷﾐ ヴWﾉ;ヮゲWS Gヴ;┗Wゲげ 
disease. However severe eye disease and pregnancy strongly influenced choice in favour of 
surgery. Surgeons underestimated the success of radioiodine (P<0.01) and were more likely to 
recommend thyroidectomy than physicians.  
Conclusions: This survey demonstrates significant variation in cliniciaﾐゲげ ヮWヴIWヮデｷﾗﾐゲ ﾗa ヴｷゲﾆゲ ﾗa 
デヴW;デﾏWﾐデ ;ﾐS デｴWｷヴ IｴﾗｷIW ﾗa ﾏ;ﾐ;ｪWﾏWﾐデ ﾗヮデｷﾗﾐゲ aﾗヴ ヴWﾉ;ヮゲWS Gヴ;┗Wゲげ SｷゲW;ゲWく TｴW ┗;ヴｷ;デｷﾗﾐ 
appeared to be dependent on patient and disease specific factors as well as physician experience, 
gender and speciality.   
 
Main messages 
 The survey demonstrates sSignificant variation in management of Gravesげ disease across 
UK 
 Surgery was more likely to be recommended in patients with severe Gヴ;┗Wゲげ thyroid eye 
disease and pregnancy.  
 CﾉｷﾐｷIｷ;ﾐゲげ ヮWヴIWヮデｷﾗﾐゲ of effectiveness and risk of treatment options in Gravesげ SｷゲW;ゲW 
varied widely.Physicians and Surgeonsげ have different approaches to the management of 
relapsed Gヴ;┗Wゲげdisease.  
Research Questions 
 
 Iゲ ヴWﾉ;ヮゲWS Gヴ;┗Wゲげ SｷゲW;ゲW デヴW;デWS ;ヮヮヴﾗヮヴｷ;デWﾉ┞い 
 What are the outcomes (effectiveness and risks) following the use of various treatment 
options in are the actual risks of Ggヴ;┗Wゲげ SｷゲW;ゲWs management in the UK? 
 How does surgery compare with radio-iodine in the management of Gravesげ SｷゲW;ゲW ﾗ┗Wヴ;ﾉﾉ 
and in specific subgroups? 
 Should there be nNational guidelines and would these improve in the UK for the 
ﾏ;ﾐ;ｪWﾏWﾐデ ﾗa Gヴ;┗Wゲげ SｷゲW;ゲW in the UK? 
  
Formatted: (none)
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BACKGROUND 
Gヴ;┗Wゲげ SｷゲW;ゲW ｷゲ デｴW ﾏﾗゲデ aヴWケ┌Wﾐデ I;┌ゲW ﾗa ｴ┞ヮWヴデｴ┞ヴﾗｷSｷゲﾏ in iodine-replete countries. The 
production of autoantibodies against the thyroid stimulating hormone receptor (TSH-receptor) 
results in hyperplasia and hypertrophy of thyroid follicles and subsequent increase in thyroxine 
synthesis and release. The clinical manifestations of Gravesげ disease include those due to 
hyperthyroidism (such as tachycardia, weight loss, diarrhoea, menstrual irregularities and 
sweating) as well as those specific to Gravesげ disease, including a diffuse goitre and signs and 
symptoms of infiltrative eye disease  (such as periorbital oedema, proptosis, ophthalmoplegia).  
 
Following a diagnosis of Gヴ;┗Wゲげ SｷゲW;ゲWが antithyroid drugs (ATDs) including carbimazole and 
propylthiouracil are used to control hyperthyroidism. Although these are very effective, they are 
associated with high rates of relapse[1,2]. For patients with relapsed hyperthyroidism or disease 
uncontrolled with ATDs, alternative treatment options such as radioiodine (RAI) therapy and 
surgery (most commonly total thyroidectomy) are considered to offer definitive treatment; each 
with its risks and benefits. 
 
The precise indications for these options have been debated and management practices are 
varied, particularly in the uncomplicated patient[3].  Patient preference also plays a large role in 
the decision to undergo either surgery or radioiodine. The rates of success, complication rates, 
ゲW┗Wヴｷデ┞ ﾗa Gヴ;┗Wゲげ SｷゲW;ゲWが ;┗;ｷﾉ;Hｷﾉｷデ┞ ﾗa ﾉﾗI;ﾉ a;IｷﾉｷデｷWゲ ;ﾐS W┝ヮWヴデｷゲW also influence decision 
ﾏ;ﾆｷﾐｪく Hﾗ┘W┗Wヴが デｴW IﾉｷﾐｷIｷ;ﾐげゲ ;ゲゲWゲゲﾏWﾐデ ﾗa デｴWゲW a;Iデﾗヴゲ ;ﾐS デｴWｷヴ ヮWヴIWヮデｷﾗﾐゲ ;ﾐS 
preferences will inevitably iﾐaﾉ┌WﾐIW デｴW ヮ;デｷWﾐデげゲ SWIｷゲｷﾗﾐ ;ﾐS デｴW SWIｷゲｷﾗﾐ ﾏ;ﾆｷﾐｪ ヮヴﾗIWゲゲく  
 
Previously published papers have demonstrated the wide variation in practice within Europe and 
the world relating togarding デｴW デヴW;デﾏWﾐデ ﾗa ヴWﾉ;ヮゲWS Gヴ;┗Wゲげ Ddisease. In 2000, Escobar-Jimenez 
et al[4] ゲ┌ヴ┗W┞WS EﾐSﾗIヴｷﾐW ┌ﾐｷデゲ ｷﾐ “ヮ;ｷﾐ デﾗ W┝ヮﾉﾗヴW デｴWｷヴ ﾏ;ﾐ;ｪWﾏWﾐデ ﾗa ┌ﾐIﾗﾏヮﾉｷI;デWS Gヴ;┗Wゲげ 
disease and relapsed patients looking at factors that influenced their decision making. Vaidya et al 
[5] reported on a UK survey of 698 clinicians(2008) discussed Gヴ;┗Wゲげ SｷゲW;ゲW management in the 
UK in the year 2008, but the study focussed primarilymainly concentrated on the use of radio-
iodine with little information regarding surgical practice. 
“ﾗﾏW ゲデ┌SｷWゲ ｴ;┗W W┝ヮﾉﾗヴWS IﾉｷﾐｷIｷ;ﾐゲげ ┗ｷW┘ゲ ﾗﾐ デｴW ﾏ;ﾐ;ｪWﾏWﾐデ ﾗa Gヴ;┗Wゲげ SｷゲW;ゲW ;ﾐS have 
found significant variation in practices. In 2008 Vaidya et al[4] reported on a UK survey of 698 
consultants involved in the management of thyroid disease. Various scenarios were discussed. In 
an uncomplicated thyrotoxic patient, 80% chose ATDs, 19% radioiodine, and 0.4% thyroidectomy. 
However in the presence of active thyroid eye disease, no respondent chose radioiodine. In 
patients with inactive eye disease, 46% would give radioiodine with steroid cover, and 26% would 
give radioiodine without steroid cover. Although the study was comprehensive for matters 
regarding radioiodine therapy, there is limited information on surgical preference.  
 
In 2000, Escobar-Jimenez et al[5] reported the results of a survey of Endocrine units in Spain. Ten 
scenarios were presented, each of which varied in factors that could influence treatment. In 
ヮ;デｷWﾐデゲ ヮヴWゲWﾐデｷﾐｪ ┘ｷデｴ ┌ﾐIﾗﾏヮﾉｷI;デWS Gヴ;┗Wゲげ SｷゲW;ゲWが ΓΒХ IｴﾗゲW ATDs as the initial treatment 
;ﾐS ヲХ ヴ;SｷﾗｷﾗSｷﾐWく Iﾐ ヮ;デｷWﾐデゲ ┘ｷデｴ ヴWﾉ;ヮゲWS Gヴ;┗Wゲげ SｷゲW;ゲWが 61% of responders preferred 
radioiodine except in pregnancy where 12% would use surgery and the remainder would use a 
further course of ATDs.  
 
In 2011 a survey was conducted by Burch et al[3] to assess international practice in the diagnosis 
;ﾐS ﾏ;ﾐ;ｪWﾏWﾐデ ﾗa Gヴ;┗Wゲげ SｷゲW;ゲW ;ﾏﾗﾐｪゲデ ヮｴ┞ゲｷIｷ;ﾐゲ ;ﾐS ゲ┌ヴｪWﾗﾐゲ ┌ゲｷﾐｪ ┗;ヴｷﾗ┌ゲ ゲIWﾐ;ヴｷﾗゲく TｴW 
vast majority of the respondents first case was of non-IﾗﾏヮﾉｷI;デWS Gヴ;┗Wゲげ SｷゲW;ゲWく E┌ヴﾗヮW;ﾐ 
responders chose between antithyroid drugs (85.7%), radioiodine (13.3%) and surgery (1%). This 
practice differed to North America where the choice of ATD, radioiodine and surgery were made 
in 40.5%, 58.6% and 0.9% respectively. In the presence of eye disease or pregnancy, antithyroid 
drugs and thyroidectomy were preferred to radioiodine.majority of respondents (92.2%) Of note, 
92.2% of the respondents were specialists in adult Endocrinology (92.2%), with only 0.6% in 
General Surgery and 2.2% in Nuclear Medicine[3]. This may have potentially influenced results in 
favour of medical treatment. In 2013, the same questionnaire as that used by Burch et al in 2011, 
was sent to the European Thyroid Association members [6]. They reported no significant changes 
from previous surveys conducted in Europe on the treatment of Gヴ;┗Wゲげ disease[7], but 
demonstratedongoing significant differences between North America and Europe[3]. In 
uncomplicated first presentation of Gヴ;┗Wゲげ disease, 83.8% of survey responders chose ATDs as 
first line treatment (similar to 1987 survey), 14.1% radioiodine and surgery in just 2.1%. Neither 
Both of these two studies papers did not addressed デｴW ﾏ;ﾐ;ｪWﾏWﾐデ ﾗa ヴWﾉ;ヮゲWS Gヴ;┗Wゲげ SｷゲW;ゲWく 
 
To date, there are no nationalcurrent British ｪ┌ｷSWﾉｷﾐWゲ aﾗヴ デｴW デヴW;デﾏWﾐデ ﾗa Gヴ;┗Wゲげ SｷゲW;ゲW ornor 
any studies that explore the factors influencing choice of surgery and radioiodine in the definitive 
treatment of relapsed Gヴ;┗Wゲげ SｷゲW;ゲW ｷﾐ デｴW UK, particularly in the scenario of relapse. In addition, 
IﾉｷﾐｷIｷ;ﾐゲげ ヮヴWaWヴWﾐIWゲ ;ﾐS ヮWヴIWヮデｷﾗﾐゲ ﾗa ゲ┌IIWゲゲ ;ﾐS IﾗﾏヮﾉｷI;デｷﾗﾐ ヴ;デWゲ in this scenario are, as 
yet, unexplored.  
 
The aim of this study was to survey the preferences and perceptions of UK clinicians on the role of 
surgery and RAI in the management of relapsed Gヴ;┗Wゲげ SｷゲW;ゲWく 
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METHODS 
Between December 2013 and January 2014, a survey (see Appendix) was sent out to all Consultant 
members of the British Thyroid Association (BTA), Society of Endocrinology (SFE) and the British 
Association of Endocrine and Thyroid Surgeons (BAETS) involvWS ｷﾐ デｴW デヴW;デﾏWﾐデ ﾗa Gヴ;┗Wゲげ 
diseaseく Tｴｷゲ ┘;ゲ IﾗﾐS┌IデWS ┌ゲｷﾐｪ デｴW ﾗﾐﾉｷﾐW デﾗﾗﾉ けゲ┌ヴ┗W┞ﾏﾗﾐﾆW┞くIﾗﾏげ and reminders sent 2 
weeks later. To ensure anonymity, no names or personal details were requested. Information on 
speciality, year of graduation in Medicine, county of practice and gender was collected to enable 
us to detect duplicate responses and to evaluate if any of these demographic differences 
influenced IﾉｷﾐｷIｷ;ﾐゲげ ヮWヴIWヮデｷﾗﾐゲ ;ﾐS ヮヴWaWヴWﾐIWゲく TｴW survey start times and IP addresses of 
respondents collected automatically were also used to detect duplicate responses made in error 
(ゲ┌Iｴ ;ゲ ヮヴWゲゲｷﾐｪ デｴW さゲ┌Hﾏｷデざ button more than once).  
 
Clinical specialities surveyed included Endocrinology, Endocrine Surgery, Head & Neck Surgery as 
well as Nuclear Medicine. The survey consisted of initial questions establishing the respondersげ 
status as UK consultants and then collecting information on speciality, geography, gender, year 
ゲｷﾐIW ｪヴ;S┌;デｷﾗﾐが ;ﾐS デｴW ﾐ┌ﾏHWヴ ﾗa Gヴ;┗Wゲげ ヮ;デｷWﾐデゲ ゲWWﾐ ヮWヴ ┞W;ヴく “┌HゲWケ┌Wﾐデ ケ┌Wゲデｷﾗﾐゲ 
W┝ヮﾉﾗヴWS ヴW;ゲﾗﾐゲ aﾗヴ IﾗﾏﾏWﾐIｷﾐｪ ATDゲ ｷﾐ ﾐW┘ﾉ┞ Sｷ;ｪﾐﾗゲWS Gヴ;┗Wゲげ SｷゲW;ゲW ;ﾐS ┘ｴ;デ ヮ;デｷWﾐデ 
factors influencWS IﾉｷﾐｷIｷ;ﾐゲげ SWIｷゲｷﾗﾐゲ ﾗﾐ SWaｷﾐｷデｷ┗W デヴW;デﾏWﾐデ ｷﾐ ヴWﾉ;ヮゲWS Gヴ;┗Wゲげ SｷゲW;ゲWく TｴW 
side effects quoted to patients for either radioactive iodine or surgery and the cliniciansげ 
perception of what risks influenced patient decision-making was also examined. The final question 
;ゲﾆWS ┘ｴ;デ デｴW IﾉｷﾐｷIｷ;ﾐゲげ ヮヴWaWヴWﾐIW ┘ﾗ┌ﾉS HW ｷa デｴW┞ ┘WヴW デｴW ヮ;デｷWﾐデ ┘ｷデｴ ヴWﾉ;ヮゲWSが 
┌ﾐIﾗﾏヮﾉｷI;デWS Gヴ;┗Wゲげ SｷゲW;ゲWく  
 
Questionnaires were completed on surveymonkey.com. The results were downloaded to a 
Microsoft Excel 2007 worksheet and exported to IBM SPSS version 21 statistical software for 
Formatted: Line spacing:  single
further analysis. Evaluation for potential duplicate or multiple entries was performed, as explained 
above. For incomplete surveys, available answers were included in the analysis. In questions 
where ranges or open text answers were given, certain assumptions were made. Data presented 
as ratios were changed to percentages. Averages were calculated for data presented as ranges, 
┌ﾐﾉWゲゲ デｴW ヴ;ﾐｪW ┘;ゲ ┗Wヴ┞ ┘ｷSW ふaﾗヴ Wｪく бヲヵぶく Ia さбざ ﾗヴ さаざ ┘;ゲ ┌ゲWS デﾗ SWゲcribe a value, 10% was 
added to or subtracted from the value. If two values were presented for different groups (i.e. male 
or female; young or old), the average was taken. If two values are given for immediate and later 
relapse, the total was taken (or the larger number if this was thought to incorporate those that 
have relapsed before). If personal results were presented alongside literature, the personal results 
were taken. If the response rates to first and second course of antithyroid drugs were presented, 
only the rates from the first course were included in the analysis. 
 
Data on gender, specialty, county, and other categorical or ordinal responses to questions were 
reported as frequencies or percentages.   Data on year since graduation, and other quantitative 
data were reported using median and range (as none of our quantitative variables were normally 
distributed). Answers in text were grouped into similar categories. For example, 30 responses 
related to voice (change in voice, vocal cord weakness, hoarseness, recurrent laryngeal nerve palsy 
etc.) and these ┘WヴW ｪヴﾗ┌ヮWS ｷﾐ ; ゲヮWIｷaｷI I;デWｪﾗヴ┞ ﾗa け┗ﾗｷIW Iｴ;ﾐｪWげ aﾗヴ ゲ┌ヴｪｷI;ﾉ IﾗﾏヮﾉｷI;デｷﾗﾐゲく 
TｴW ヴWゲヮﾗﾐゲWゲ ┘WヴW Iﾗﾏヮ;ヴWS H┞ ゲヮWIｷ;ﾉデ┞が ヴWｪｷﾗﾐが ｪWﾐSWヴが ┗ﾗﾉ┌ﾏW ﾗa Gヴ;┗Wゲげ SｷゲW;ゲW ゲWWﾐ ;ﾐS 
years since graduation where appropriate. Binary data between groups were compared using the 
PW;ヴゲﾗﾐ Iｴｷ ゲケ┌;ヴW デWゲデ ┘ｷデｴ Iﾗﾐデｷﾐ┌ｷデ┞ IﾗヴヴWIデｷﾗﾐ ふﾗヴ FｷゲｴWヴげゲ W┝;Iデ デWゲデぶく Cﾗﾐデｷﾐ┌ﾗ┌ゲ S;デ; ┘;ゲ 
compared using the Mann-Whitney U test (for two groups) or Kruskal-Wallis test (for more than 
two groups). The significance was set at the 5% level (p=0.05).  
 






169 responses were received but 11 were excluded either for duplicate responses (n=4) or 
because the respondents were not practising consultants in the UK (n=7). The demographics of 
the respondents are displayed in Table 1. 
  
Table 1. Demographic features of clinicians who responded to the survey 
 
Demographic 
Subcategory Number (%) 
Gender (n=154) Male 115 (74.7%) 
Female 39 (25.3%) 
Specialty (n=158) Endocrinology 108 (68.4%) 
Surgery 50 (31.6%) 
Region (n=156) East Midlands 8 (5.1%) 
East of England 18 (11.5%) 
London 20 (12.8%) 
North East England 8 (5.1%) 
North West England 16 (10.3%) 
Northern Ireland 5 (3.2%) 
Scotland 17 (10.9%) 
South East England 21 (13.5%) 
South West England 15 (9.6%) 
Wales 5 (3.2%) 
West Midlands 6 (3.8%) 
Yorkshire and the Humber 17 (10.9%) 
Vﾗﾉ┌ﾏW ﾗa Gヴ;┗Wゲげ SｷゲW;ゲW ゲWWﾐ ヮWヴ ┞W;ヴ 
(n=156) 
Less than 10 16 (10.3%) 
10 to 30 61 (39.1%) 
More than 30 79 (50.6%) 
Note: regions grouped by Eurostat Nomenclature of Territorial Units for statistics (NUTS 1) 
  
 
The median (range) time since graduation for the cohort (n=155) was 25 (12-43) years. The 
proportion of females was 28.6% in Endocrinology and 18.4% in Surgery. Regarding the rationale 
for initiating antithyroid drugs in patients with newly diagnosed Graveゲげ SｷゲW;ゲW, 60.2% of 
physicians and 63.6% surgeons commenced ATDs to make the patients euthyroid with subsequent 
remission expected on withdrawal of ATDs. 9.1% of surgeons, however, used ATDs in preparation 
to definitive surgery compared to only 1.9% of physicians.  38% and 27.3% of physicians and 
surgeons respectively answered they used ATDs for both definitive treatment as well as a bridge 
to surgery. Their reasons were patient preference (n=11), other comorbidities (n=7), presence of 
large goitre (n=7) or an older patient (n=7). All the physicians answered they would commence 
ATDs for the reasons discussed but over half of the (54%) either ;ﾐゲ┘WヴWS け┌ﾐゲ┌ヴWっI ;ﾏ ﾐﾗデ 
ｷﾐ┗ﾗﾉ┗WS ｷﾐ デｴｷゲ ゲデ;ｪWげ ﾗヴ left the question unanswered. 
 
The second question determined the influence of clinical factors on recommendations for 
SWaｷﾐｷデｷ┗W デヴW;デﾏWﾐデ ﾗa ヴWﾉ;ヮゲWS Gヴ;┗Wゲげ SｷゲW;ゲW. Overall, clinicians were more likely to 
recommend surgery than radioiodine in the presence of the factors mentioned other than mild 
eye disease. The influence of speciality on the recommendation for treatment in context of the 
described factors are summarised in a cluster bar chart (Figure 1). Surgeons were significantly 
more likely than physicians to recommend surgery in the presence of mild (p<0.001) and 
moderate eye disease (p=0.002), large goitre (p<0.001), children at work/home (p=0.011) and 
young women intending to start a family (p<0.001).  
 
Similar analyses  (Figure 2) ┘WヴW ヮWヴaﾗヴﾏWS デﾗ ﾉﾗﾗﾆ ;デ デｴW ｷﾐaﾉ┌WﾐIW ﾗa ｪWﾐSWヴ ﾗﾐ IﾉｷﾐｷIｷ;ﾐゲげ 
preference for surgery or radioiodine. Female clinicians were significantly more likely than their 
male counterparts to recommend surgery in the presence of severe eye disease (p=0.017) and 
lactation (p=0.008) (data not shown). 
 
The experience of consultants (in terms of years since graduation) did not appear to influence 
ヮヴWaWヴWﾐIW aﾗヴ ヴ;SｷﾗｷﾗSｷﾐW ﾗヴ ゲ┌ヴｪWヴ┞ ｷﾐ Gヴ;┗Wゲげ SｷゲW;ゲW ;ゲゲﾗIｷ;デWS ┘ｷデｴ デｴW a;Iデﾗヴゲ SWゲIヴｷHWS 
(data not shown). 
 
The influence eaffect ﾗa ┗ﾗﾉ┌ﾏW ﾗa Gヴ;┗Wゲげ SｷゲW;ゲW ゲWWﾐ H┞ IﾉｷﾐｷIｷ;ﾐゲ ヮWヴ ┞W;ヴ ┘;ゲ ;ﾉゲﾗ W┝;ﾏｷﾐWS 
and assessed using Kruskal-Wallis test. (Figure 3). Although the majority of clinicians across all 
subgroups (by volume) would recommend surgery in the presence of all of the factors listed, 
IﾉｷﾐｷIｷ;ﾐゲ ┘ｴﾗ ゲWW ｴｷｪｴ ┗ﾗﾉ┌ﾏWゲ ﾗa Gヴ;┗Wゲげ SｷゲW;ゲW ┘WヴW ゲｷｪﾐｷaｷI;ﾐデﾉ┞ ﾉWゲゲ ﾉｷﾆWﾉ┞ デﾗ ヴWIﾗﾏﾏWﾐS 
surgery in patients with a large goitre (p<0.001) and in women intending to start a family 
(p=0.004).  
 
Clinicians were then asked what they thought influenced patientsげ choices regarding their 
treatment. The majority of clinicians agreed that most of the factors suggested would influence 
ヮ;デｷWﾐデ SWIｷゲｷﾗﾐゲ W┝IWヮデ aﾗヴ けゲﾉﾗ┘っ┌ﾐヮヴWSｷIデ;HﾉW ヴWゲヮﾗﾐゲW デﾗ ヴ;SｷﾗｷﾗSｷﾐWげ. The responses to this 
question were compared in subgroups defined by specialty (Figure 24) and assessed with Mann-
Whitney U test. Surgeons were less likely to agree that factors that related to surgery に fear of 
surgery (p=0.001) and complications of general anaesthesia (p=0.037) に influenced patient 
decisions with regards to definitive management. Endocrinologists were more likely to strongly 
disagree that the slow or unpredictable response with radioiodine (p<0.001) was a factor that 
patients may consider.  
 
The survey also examined how clinical speciality may influence the risks mentioned to patients 
┘ｴWﾐ SｷゲI┌ゲゲｷﾐｪ SWaｷﾐｷデｷ┗W ﾏ;ﾐ;ｪWﾏWﾐデ ﾗa Gヴ;┗Wゲげ SｷゲW;ゲW ｷ.e. surgery or radioactive iodine. As 
shown in Table 2, surgeons were more likely to quote a higher rate of failure (p=0.005) or relapse 
(p=0.003) with radioiodine and the risk of long-term hypocalcaemia (p=0.016) than physicians. 
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When questioned about what risks were quoted to patients when discussing surgery and 
radioactive iodine, answers varied widely. The main complications of radioiodine mentioned to 
patients were hypothyroidism, exacerbation of thyroid eye disease and radiation protection 
issues. When discussing surgical treatment, the risks discussed frequently were scarring, 
hypothyroidism and infection. Only 18.9% said they would mention risk of voice damage and only 
12.6% mentioned risk of post-operative hypocalcaemia. 
 
Clinicians were also asked on the rates of different definitive treatment taken up by their patients. 
Their responses by specialty and geography are displayed in Table 3 and Figure 35 respectively. 
Table 3 shows a statistically significant difference in the perceived uptake of treatment between 
surgeons and physicians. However, it should be noted that there were only 109 responses to this 
question, of which only eight were surgeons. 
 
Table 3. Rates of patients who undergo second-round antithyroid drugs, radioiodine and surgery 
as perceived by UK clinicians 








































When evaluated by region, the use of radioiodine did not appear to significantly vary between 
regions, but the choice of surgery and second round antithyroid therapy did. The vast majority of 
patients in Wales appeared to undergo radioiodine for relapsed Gravesげ SｷゲW;ゲW, while this was 
least frequent in Scotland. Of the three options, surgery is used least frequently in most regions, 
particularly in Northern Ireland and Wales. The most frequent use of surgery is in the South East 
and East Midlands (25%). The significant differences in choice of second-round antithyroid 
treatment were demonstrated by the uncommon use in Wales (2%) compared to > 10% in many 
parts of England and > 50% in Scotland.  
 
The final question asked the clinicians to decide treatment they would have if they were suffering 
from uncomplicated relapsed Gヴ;┗Wゲげ disease. The majority (n=95) chose radioiodine in this 
situation; 37 chose antithyroid drugs and 17 surgery (of which 12 were surgeons). Seven were 
unsure, whilst two preferred not to say (Figure 46).  Speciality was found to influence the choice of 
therapy in favour of the treatment in which the individual was involved (Pearson Chi-square 
p=0.001). Gender, volume and experience (median number of years since graduation) did not 
;ヮヮW;ヴ デﾗ ｷﾐaﾉ┌WﾐIW デｴWｷヴ SWIｷゲｷﾗﾐ ふPW;ヴゲﾗﾐげゲ Cｴｷ-ゲケ┌;ヴW デWゲデ ヮЭヰくΓΑンき PW;ヴゲﾗﾐげゲ Cｴｷ-square test 





Current practices in the definitive treatment of Gravesげ disease in the UK are influenced by 
ヮ;デｷWﾐデゲげ IｴﾗｷIWが ゲﾗIｷ;ﾉ IｷヴI┌ﾏゲデ;ﾐIWゲ ;ﾐS IﾉｷﾐｷIｷ;ﾐゲげ W┝ヮWヴｷWﾐIWく Tｴｷゲ ｷゲ WゲヮWIｷ;ﾉﾉ┞ true for relapsed 
Gヴ;┗Wゲげ SｷゲW;ゲWく Prior to this survey, these patterns have been explored in Europe[4,6][5,6] USA, 
and worldwide [3] but a detailed evaluation amongst UK consultants has not been performed.  
 
Our survey revealed that the majority of clinicians would routinely start antithyroid medication 
with the aim of inducing remission in an ┌ﾐIﾗﾏヮﾉｷI;デWSが aｷヴゲデ ヮヴWゲWﾐデ;デｷﾗﾐ ﾗa Gヴ;┗Wゲげ disease. Only 
two physicians and two surgeons would start antithyroid medication as a bridge to definitive 
treatment in all of their patients. The reasons for adopting either of the two approaches in a 
selective manner in subgroups of patients were reviewed in Table 3. Patient preference seems to 
HW ; Iﾗﾏﾏﾗﾐ ｷﾐaﾉ┌WﾐIW ﾗﾐ デｴW ヮﾗﾉｷI┞ ﾗa ┌ゲｷﾐｪ ;ﾐデｷデｴ┞ヴﾗｷS Sヴ┌ｪゲ ｷﾐ ﾐW┘ﾉ┞ Sｷ;ｪﾐﾗゲWS Gヴ;┗Wゲげ 
disease as a bridge to definitive treatment. Comorbidity has also been quoted as a reason, which is 
similar to another UK-based survey on the use of radioiodine[5][4]. This is reasonable given the 
relative need for more rapid and effective treatment of hyperthyroidism in some patients with 
cardiac comorbidity which has the potential to lead to heart failure and sudden cardiac death[8]. 
Large goitre was also considered as an indication for the early adoption of definitive treatment in 
other surveys[4,5]. The American Thyroid Association and American Association of Clinical 
Endocrinologists support using antithyroid medication as a bridge to definitive therapy in 
compressive/symptomatic goitres or goitres over 80 g[9]. Older age as a reason for using 
antithyroid drugs as a bridge to definitive treatment is debatable. Surveys have found a relatively 
greater preference for definitive treatment (primarily radioiodine) in the elderly[4,5]. In contrast, 
American guidelines suggest that antithyroid drugs should be favoured in older age, although this 
has been described in the context of risk of surgical complications[9]. Klein et al highlights that 
older patients are more likely to have more cardiac comorbidities, and are less likely to revert back 
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to sinus rhythm with treatment of hyperthyroidism[8]. They therefore suggest that more effective 
control over thyrotoxicosis may be preferable to trial of antithyroid medication treatment that has 
a potential relapse rate of approximately 60-70%[10].  
 
This survey has found that surgery is the preferred option for the majority of consultants in 
ヴWﾉ;ヮゲWS Gヴ;┗Wゲげ SｷゲW;ゲW IﾗﾏヮﾉｷI;デWS H┞ デｴW ヮヴWゲWﾐIW ﾗa ;ﾐ┞ ﾗa デｴW IﾉｷﾐｷI;ﾉ ;ﾐS ゲﾗIｷ;ﾉ aW;デ┌ヴWゲ 
described (Table 3). Mild eye disease may be an exception to this trend - 42.7% have a slight or 
strong preference for surgery, and 47.1% were either unsure or had no preference.  This survey 
was different to other studies in that it looked predominantly at factors influencing treatment of 
ヴWI┌ヴヴWﾐデ Gヴ;┗Wゲげ SｷゲW;ゲWが ヴ;デher than at initial presentation. Although recurrence was described 
in Burch and Vaidya et al[3,5], factors exploring choice of treatment in those studies were in 
relation to initial presentation. Escobar-Jimenez et al[4] looked at recurrence after previous ATD 
and surgery as well as that complicated by pregnancy. Certain findings were comparable across 
these previous studies. Eye disease influences choice away from radioiodine[3,5]; however if eye 
disease is inactive, 46% of clinicians would feel comfortable treating with radioiodine with the 
addition of steroids[5]. This is similar to the results of our survey. Large goitre was more often 
デヴW;デWS ┘ｷデｴ ゲ┌ヴｪWヴ┞ ｷﾐ デｴW ｷﾐｷデｷ;ﾉ ヮヴWゲWﾐデ;デｷﾗﾐ ﾗa Gヴ;┗Wゲげ SｷゲW;ゲW ｷﾐ “ヮ;ｷﾐく Fﾗヴ ヮヴWｪﾐ;ﾐデ ヮ;デients 
with relapse, antithyroid medication was the preferred option for the vast majority of patients[4]. 
In our survey, in which antithyroid medication was not an option, 73% had a strong surgical 
preference for surgery in pregnant patients. 
 
The majority of consultants considered that complications of surgery or anaesthesia and fear of 
surgery could influence patients in their decision, although surgeons were less likely to agree that 
this was the case (p=0.037 and p=0.001 respectively). 80.8% of all consultants agreed that the 
ヴ;Sｷ;デｷﾗﾐ ヴｷゲﾆ デﾗ IｴｷﾉSヴWﾐ ;ﾐS ﾗデｴWヴ ┗┌ﾉﾐWヴ;HﾉW ヮWﾗヮﾉW ┘;ゲ ﾉｷﾆWﾉ┞ デﾗ ｷﾐaﾉ┌WﾐIW デｴW ヮ;デｷWﾐデげゲ SWIｷsion 
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for definitive therapy. Fear of radioiodine with regards to cancer, and slow or unpredictable 
response with radioiodine was also considered to be influential, although to a lesser extent.  
 
Although preference for recommending definitive treatment option in patients with relapsed, but 
┌ﾐIﾗﾏヮﾉｷI;デWS Gヴ;┗Wゲげ SｷゲW;ゲW ┘;ゲ ﾐﾗデ W┝ヮﾉﾗヴWSが デｴW ヮWヴゲﾗﾐ;ﾉ ヮヴWaWヴWﾐIW ﾗa Iﾗﾐゲ┌ﾉデ;ﾐデゲ ゲ┌ヴ┗W┞WS 
was examined. 60.5% would undergo radioiodine as their preferred therapy choice of therapy. The 
significant influence of speciality on the preference (p<0.001) provides an interesting insight into 
personal choice of treatment. Only 4.6% of endocrinologists would prefer to have surgery, 
compared to 24.5% of surgeons. It needs to be emphasised that the scenario specifically excluded 
factors that may influence choice of treatment and that these preferences may be different in the 
presence of the variables that have been explored previously.   
 
The perceived numbers of patients who undergo the three treatments following relapse (Table 3) 
shows a significant difference in treatment pathways across the UK. Radioiodine is considered to 
be used in 50.0% (median; range 4.0-97.0) of cases of relapse; second round antithyroid 
medication is used by 25.0% (0.0-96.0) and surgery in 10.0% (0.0-100.0). Preference for 
ヴ;SｷﾗｷﾗSｷﾐW ｷﾐ ヴWﾉ;ヮゲWS Gヴ;┗Wゲげ SｷゲW;ゲW ｷゲ ;ﾉゲﾗ ｷﾉﾉ┌ゲデヴ;デWS ｷﾐ ﾗデｴWヴ ゲデ┌SｷWゲ including physicians in 
the UK [5] and mainland Europe[4]. Seven consultants said that less than 5% of patients would 
undergo a second round treatment with antithyroid drugs in their centre (an additional four did 
not provide an answer for antithyroid drugs but a total of 100% was provided for radioiodine plus 
surgery). In contrast, eleven said that 80% or more would choose antithyroid drugsthis option. The 
total of all answers provided in these questions had a total of 90-110%, (where some 
ｷﾐデWヴヮヴWデ;デｷﾗﾐ ﾗa ヴ;ﾐｪWゲ ﾗヴ けﾏﾗヴWっﾉWゲゲ デｴ;ﾐげ ;ﾐゲ┘Wヴゲ ﾏ;┞ ;IIﾗ┌ﾐデ aﾗヴ SｷaaWヴWﾐIWゲぶが ﾗデｴWヴ デｴ;ﾐ 
from one responder. This establishes that the majority of consultants interpreted the question 
correctly and considered second round antithyroid drug treatment to be a separate regime from 
that which is used to prepare patients for radioiodine or surgery. The use of radioiodine did not 
differ between the regions (p=0.125), while repeat treatment with antithyroid drugs (p=0.022) and 
surgery (p=0.011) differed significantly. This is illustrated in Figure 5. 
 
Both endocrinologists and surgeons consider that 50.0% (median; range 10.0-70.0) of patients will 
relapse following antithyroid medication. However, widely ranging rates of failure and relapse 
with radioiodine, permanent laryngeal nerve injury and long-term hypocalcaemia were quoted by 
clinicians across the UK (Table 2). Risk of permanent laryngeal nerve injury did not differ by 
specialty, and was considered to be around 1.0% (0.0-8.0). Two surgeons considered that relapse 
following radioiodine was ten times higher than the median value provided by all consultants. 
Other than for relapse following antithyroid medication, theall highest values stated by 
consultants were more than six times the median value. Although the surgical risks were described 
;ゲ けヮWヴﾏ;ﾐWﾐデげが Iﾗﾐゲ┌ﾉデ;ﾐデゲ ﾏ;┞ ｴ;┗W ;ゲゲ┌ﾏWS デｴ;デ デｴｷゲ ┘;ゲ aﾗヴ けデヴ;ﾐゲｷWﾐデげ ﾗヴ デﾗデ;ﾉ ┗;ﾉ┌Wゲく TｴW 
differences in the perceptions of risk for complicationsが a;ｷﾉ┌ヴW ;ﾐS ヴWﾉ;ヮゲW ｷﾐ Gヴ;┗Wゲげ SｷゲW;ゲW 
treatments across the UK strengthen the case for the need for empiric data from the UK 
population. 
 
TｴW IﾉｷﾐｷIｷ;ﾐげゲ ゲヮWIｷ;ﾉity was strongly associated with personal choice and preference for specific 
treatments in the presence of specific patient- and disease-related factors. Surgeons had more 
positive views of surgery.  
 
Other interesting findings from this study were that female clinicians were more likely to 
recommend surgery in the presence of severe eye disease (p=0.017) and lactation (p=0.008); and 
high volume consultants were less likely to strongly recommend surgery in patients with a large 
goitre (p<0.001) or those intending to start a family (p=0.004). Given the exploratory nature of this 
study, these should only be considered as preliminary findings. However, it is clear that clinician 
related factors can significantly influence treatment recommendations. 
 
As with surveys in general, there are a few limitations, which may influence the conclusions of this 
study. Despite piloting the study locally, there was a suggestion of misinterpretation of some of 
the questions by a number of respondents from the comments in the free text area. In addition, 
we asked consultants for their interpretation of practice within their centre, which may not 
correlate with actual practice. Occasionally, the respondents used ratios, ranges, and text answers 
for questions requiring percentages. In these cases, ┘W ┌ゲWS ; ゲWデ ﾗa けヴ┌ﾉWゲげ to attempt to 
summarise the responses. However, this may have introduced bias in interpretation of the 
answers. The same limitation applies to the attempt to group some of the responses into themes. 
The response rate is not ascertainable given the overlap of membership between the three 
societies surveyed. The response rate may have been higher with posted questionnaires, or with a 
financial incentive; however this was not logistically or financially feasible. Given the size of the 
memberships emailed, the number of responses obtained seems adequate.  
 
In conclusion, within デｴW UKが ﾏﾗゲデ IﾉｷﾐｷIｷ;ﾐゲ デヴW;デ ﾐW┘ ﾗﾐゲWデ Gヴ;┗Wゲげ SｷゲW;ゲW ┘ｷデｴ ; Iﾗ┌ヴゲW ﾗa 
antithyroid medication in the hope of achieving remission. Approximately 50% of patients are 
thought to have a relapse following treatment. Definitive treatment in the form of radioiodine is 
the preferred choice for 50% of patients (median; range 4.0-97.0); however clinicians are inclined 
to recommend surgery in the presence of moderate eye disease, large goitre, cold nodule, 
patients with children at home or young female patients intending to start a family. In the context 
of pregnancy, lactation, or severe eye disease, the majority of consultants would strongly 
recommend surgical treatment to their patients. The perceived complication and relapse rates of 
therapy varied significantly across consultants that responded to the questionnaire. Empiric data 
on failure and complication rates in the UK population is required. Discussion about the need for 
national guidelines ﾗﾐ デｴW ﾏ;ﾐ;ｪWﾏWﾐデ ﾗa Gヴ;┗Wゲげ SｷゲW;ゲW ゲｴﾗ┌ﾉS ;ﾉゲﾗ HW IﾗﾐゲｷSWヴWS. 
 




Figure 1. Comparison of preferences of physicians and surgeons for surgery or radioiodine in the 
デヴW;デﾏWﾐデ ﾗa Gヴ;┗Wゲげ SｷゲW;ゲW ｷﾐ デｴW ヮヴWゲWﾐIW ﾗa ゲヮWIｷaｷI IﾉｷﾐｷI;ﾉ ;ﾐS ゲﾗIｷ;ﾉ a;Iデﾗヴゲく ふM;ﾐﾐ-Whitney 
U test) 
 
Figure 2. Comparison of preferences of male and female clinicians for surgery or radioiodine in the 
デヴW;デﾏWﾐデ ﾗa Gヴ;┗Wゲげ SｷゲW;ゲW ｷﾐ デｴW ヮヴWゲWﾐIW ﾗa ゲヮWIｷaｷI IﾉｷﾐｷI;ﾉ ;ﾐS ゲﾗIｷ;ﾉ a;Iデﾗヴゲ ふM;ﾐﾐ-Whitney 
U test) 
 
Figure 3. Comparison of preferences for surgery or radioiodine of clinicians stratified by volume of 
Gヴ;┗Wゲげ SｷゲW;ゲW ゲWWﾐ ヮWヴ ┞W;ヴ ｷﾐ デｴW ヮヴWゲWﾐIW ﾗa ゲヮWIｷaｷI IﾉｷﾐｷI;ﾉ ;ﾐS ゲﾗIｷ;ﾉ a;Iデﾗヴゲ ふKヴ┌ゲﾆ;ﾉ-Wallis 
test) 
Figure 2.  Comparison of the perceptions of factors that influence patient decision in regards to 
definitive therapy by specialty (Mann-Whitney U test) 
Figure 3. Schematic diagram of frequency of choice of second line treatment in patients with 
ヴWﾉ;ヮゲWS Gヴ;┗Wゲげ SｷゲW;ゲW ;Iヴﾗゲゲ ヴWｪｷﾗﾐゲ ｷﾐ デｴW UK 
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